objectives The 90-90-90 target states that by 2020, 90% of people living with HIV should be diagnosed, 90% of those diagnosed treated, and 90% of those treated virally suppressed. We assessed the actions needed in each country of sub-Saharan Africa to achieve the 90-90-90 target.
Introduction
In 2014, UNAIDS established the global 90-90-90 treatment target: by 2020, 90% of all people living with HIV (PLHIV) should be aware of their status, 90% of those testing HIV positive should be on antiretroviral therapy (ART), and 90% of those on ART should be virally suppressed [1] . The ultimate aim of this ambitious target is to end the AIDS epidemic by 2030. Modelling studies have projected a reduction of nearly 90% in both new HIV infections and AIDS-related deaths until 2030 could be possible if the target is reached on time [1] .
Sub-Saharan Africa (SSA) bears the heaviest burden of the global HIV epidemic: in 2016, 69% of all PLHIV worldwide resided in the region [2] . ART was very limited in SSA until 2003, when the World Health Organization (WHO) declared the epidemic a global emergency and a global programme was established to scale-up ART free of charge in the most affected countries. Since then, the number of people on ART has increased rapidly, with 14.3 of the 20.9 million people on ART in 2017 living in SSA [3] .
Despite this remarkable progress, there are a number of challenges to reaching the 90-90-90 target, notably limited HIV testing coverage, delays in starting treatment despite recent policy changes to starting treatment as soon as HIV infection is confirmed, stock-outs of antiretroviral drugs (ARVs), treatment interruptions, disengagement from care, and limited availability of viral load monitoring [4] [5] [6] [7] . These challenges are common to many countries across SSA, but there are also differences. Each country needs to adopt strategies that focus on overcoming the most pressing problems. Building on previous analyses by UNAIDS on HIV testing coverage [8] and mathematical modelling of progression of HIV in patients receiving ART [9] [10] [11] [12] , we estimated what actions are needed in each country of SSA to reach the 90-90-90 target by 2020.
Methods
To identify the largest gaps in the cascade from HIV infection to viral suppression, we assessed the following for all SSA countries: (i) How many people need to start ART every year between 2018 and 2020 to achieve 81% coverage (90% coverage amongst the 90% of PLHIV aware of their status) amongst all PLHIV by 2020? And (ii) What needs to be done in terms of patient monitoring and retention to achieve 90% suppression amongst those on ART by 2020?
We included 41 countries, comprising all member countries of the UNAIDS East and Southern Africa and West and Central Africa regions, with the exceptions of five small countries with very limited data (Cape Verde, Comoros, Mauritius, São Tom e and Pr ıncipe, and Seychelles). We first reviewed the current situation of the epidemic and treatment cascade in each country of SSA. We estimated the current cascade from the following data sources: programme data on diagnosed and treated patients submitted to UNAIDS [2] ; modelling estimates from UNAIDS on the total infected population [2] ; estimates from Demographic and Health Surveys (DHS) and AIDS Indicator Surveys (AIS) on the proportion of infected people ever tested [13] ; and cascade estimates from the Population-based HIV Impact Assessments (PHIA) [14] . To estimate the total number of PLHIV in 2020, we collected the estimated number of PLHIV in 2016 and the average annual change over the past 5 years. We assumed that the annual change would continue the same, and using this predicted how many people would be living with HIV in 2020.
Simulation model
After the review, we applied a previously published ART forecasting model to each country [9] . The model simulates the progression of HIV from ART initiation until death in individual patients. Disease progression is represented as a sequence of health states that reflect the patient's current retention status, treatment regimen, and virological and immunological treatment responses. The transition rates between the health states have been parameterised primarily with data from routine ART programmes in South Africa, Malawi, and Zambia, which are part of the International Epidemiology Databases to Evaluate AIDS (IeDEA) collaboration's Southern African region [15] . The model is implemented using the R package gems [16, 17] . This parameterisation, assuming a cumulative probability of treatment failure of 6% at 1 year and 13% at 5 years from ART start, is likely to overestimate the true suppression level in some settings. Therefore we also ran an alternative simulation using higher virological failure rates, corresponding to 26% cumulative failure probability at one and 51% at 5 years from ART initiation (Supplementary Text S1).
We fitted the number of patients starting ART in the period 2003-2017 to the observed number of patients on ART, using an Excel tool available online [9] . For the years 2018-2020, the number of patients starting ART was chosen so that 81% coverage amongst all PLHIV would be reached by the end of 2020, and was assumed to be the same every year. This analysis was conducted for four scenarios, combining two assumptions about retention on ART and switching to a second-line regimen, and two assumptions about viral load monitoring (Table 1) . With current retention and switching, rates of drop-out and a delay between failure detection and switch to second-line were assumed as in our previous modelling studies [11, 18] ; with optimal retention and switching, we assumed that there would be no treatment interruptions in the future and patients would switch to second-line immediately after detection of failure. With targeted viral load monitoring, CD4 cell counts were monitored annually for patients on ART and viral load testing was used to confirm treatment failure; with routine viral load monitoring, all patients were tested for viral load annually. In Botswana, Malawi and South Africa routine viral load monitoring was assumed in all scenarios as national guidelines have already adopted this approach. The analysis was based on estimates of all PLHIV, but children were not explicitly considered.
Analysis of results
First, we compared the number of patients starting ART in years 2018-2020 to the 2017 estimate, to determine the increase needed in ART scale-up. Second, we analysed the raw outputs of our simulation model and calculated the proportion of patients in each simulated ART cohort who were virally suppressed. We considered the following patients as viraemic: patients who started ART, switched regimen or returned after a treatment interruption within the previous 3 months; patients failing firstline ART before switching to second-line; or patients who failed second-line ART. We performed the analysis using the main simulation for all countries, and in addition using the simulation with higher virological failure rate for the countries with latest estimated suppression <70% amongst treated patients.
We present the results concerning the needed scale-up for all countries separately. Since the internal parameters of the model do not differ between countries, we only present the pooled results on viral suppression, for the main analysis and the analysis using a higher failure rate.
Results

Review of current situation
Information on number of people living with HIV was available in the UNAIDS database for the year 2016 for all 41 reviewed countries. Complete cascades could be built for 24 countries. The proportion of PLHIV aware of their status ranged between 7% and 87%, the proportion of diagnosed patients on ART between 56% and 100%, and the proportion of treated patients who are virally suppressed between 11% and 94%. The largest gap in most countries was in awareness (with some exceptions). Moreover, the proportion who were diagnosed tended to be clearly higher in East and Southern Africa. Complete results of the review are shown in the appendix (Table S1, Figure S1 ).
Achieving the first two '90s' by 2020
According to our model, about 2.9 million people started ART in SSA in 2017, representing a 20% increase from 2016. To achieve 81% coverage amongst all PLHIV by 2020, it is sufficient to keep the average number of patients starting ART every year between 2018 and 2020 Relative change is compared with the modelled estimate of 2 871 500 people starting ART in 2017. *According to observed estimates (see previous modelling studies for parameterisation). †Routine viral load monitoring was assumed to be continued in Botswana, Malawi and South Africa.
at 2.7 million, close the 2017 level (Table 2 ). In the optimal scenario, it would be sufficient to start 2.2 million patients annually for ART to reach the target. A comparison of individual countries showed substantial differences in the needed scale-up (Figure 1 , Table S2 ). Of the 41 assessed countries, 19 (46%) will reach the two-first targets by keeping the number of patients who start ART on the 2017 level until 2020. In seven countries (17%), the ART initiation rate needs to be moderately scaled up, up to doubling the number of patients starting ART annually. In the remaining 15 (37%) countries, a more substantial increase is needed. Most of these countries are located in West and Central Africa. The situation is most critical in Liberia, Madagascar, Mauritania and South Sudan, requiring more than a 10-fold increase.
Viral suppression amongst patients receiving ART
According to our model, about 78% of all patients on ART were virally suppressed in 2016. Predicted viral suppression in 2020 was sensitive to assumptions about switching delay and treatment interruptions and availability of routine viral load monitoring (Figure 2a ). In the optimal scenario, the predicted proportion of virally suppressed patients was 94.2% (routine viral load monitoring) or 89.8% (targeted viral load monitoring). In the current scenario, the corresponding proportions were 83.7% and 81.0%.
We applied the alternative analysis with higher failure rate into the following countries with current viral suppression below 70%: Benin, Cameroon, Gabon, Lesotho, Liberia, Madagascar, Mali, Niger, and Uganda. The model estimated viral suppression at about 54% in 2016. The proportion of suppressed patients in 2020 was 51.6% in the current scenario and targeted viral load monitoring, 60.0% in the optimal scenario with targeted viral load monitoring, 64.0% in the current scenario with routine viral load monitoring, and 76.9% in the optimal scenario with routine viral load monitoring (Figure 2b ; Table S2 ).
Discussion
Achieving the 90-90-90 target in SSA will continue to require investments across the cascade of care also in the final 2 years, with priorities differing by country and region. Overall, keeping up the current speed of ART scale-up should be sufficient to reach 81% ART coverage amongst all PLHIV by 2020 in SSA. However, there are substantial differences between countries. In some countries, the target is already close and it is more important to focus on improving retention and viral suppression. In some countries, however, a substantial increase in the scale-up ART is needed.
In many East and Southern African countries, ART coverage is already close to the target. The situation has improved during the last years. The cascade estimates we found in our review were systematically higher than those in two recently published reviews, showing that several countries are making progress in reducing the gap [19, 20] . Our model suggests that the target could be reached in some countries even with a considerable decrease in the ART initiation rate. Although this is not desirable, it may be a realistic scenario: if ART coverage is already high, it will become more challenging to identify and treat the remaining PLHIV. These are likely to be amongst the harder-to-reach populations, or population groups with generally low HIV prevalence. Screening for HIV in such populations may be inefficient. It may be more efficient in these settings to focus on improving retention and viral suppression amongst patients already in care, at the same time assuring universal access to voluntary HIV testing and providing ART for all diagnosed patients.
The status of ART coverage was critical especially in West and Central Africa. In the majority of countries in this region, a multiple-fold increase in number of patients enrolling on ART annually is needed. Based on the UNAIDS database, in most of these countries the main gap is from infection to diagnosis [2] . This suggests that massive investments are needed to identify the undiagnosed PLHIV, at the same time assuring that all diagnosed patients can be treated in a timely manner. One major reason for the differences between countries is likely the differing nature of the epidemic [21, 22] . In East and Southern Africa, the epidemic is generalised, patients are predominantly young women who are easier to reach through antenatal care and due to the high prevalence, HIV has been a national priority. In West and Central Africa, overall prevalence is lower, and PLHIV are more concentrated amongst population groups who are marginalised and may face stigma and whose behaviour may be criminalised. Achievement of 90% viral suppression amongst people on ART will be challenging. According to our estimates, about 80% of the patients on ART were virally suppressed in 2016. A review of the available data showed on average similar results, and our findings should thus be applicable to most of the region, with the exception of some individual countries where notably lower suppression rates were observed or predicted. Several countries may also have already reached the target (Botswana, Malawi, Swaziland) or are close to it. In a secondary analysis we made new simulations with a considerably higher failure rate, equivalent to 26% instead of 6% risk of failure one year after treatment initiation. Since the failure rate is essentially a fixed parameter in our model, none of the interventions could lift the suppression close to the target by 2020 in this analysis. The reasons for the low suppression levels in some countries should be studied in detail to implement interventions that can efficiently improve treatment response in the context of the particular setting. On the other hand, failure rates lower than in our model have also been reported [23] , showing that with an adequate regimen and regular monitoring and adherence support, the viraemia can be kept well under control.
We found that without improvements in monitoring, switching and retention, the proportion of patients virally suppressed will stay around the current-level. Routine viral load monitoring, interventions to prevent treatment interruption and loss to care, and prompt switching to second-line therapy when indicated would increase this proportion, but the 90% level would be met only by combining multiple interventions. As the number of patients receiving and failing second-line ART increases, the availability of treatment options beyond second-line could help to ensure continued viral suppression [24] .
The incorporation of more effective and better tolerated ARVs in first-or second-line regimens could also offer opportunities to further improve virological response, although it will likely take several years before newer drugs are implemented at scale in SSA and whether these drugs will show superior effectiveness in routine programme settings remains to be seen [25] .
Limitations
Our study has several limitations. Our model is not a transmission model, and it does not predict the development of the HIV epidemic. Coverage estimates for 2020 were based on the assumption that the number of PLHIV will stay approximately stable in the future. According to the UNAIDS, the number of PLHIV in sub-Saharan Africa has increased slightly over the last few years, from 23.7 (20.9-26.7) million in 2010 to 25.5 (22.7-28.7) million in 2016. It is unlikely that this trend would substantially change in the near future, and the number of PLHIV we calculated for 2020 (26.5 million) is well in line with these estimates. This is probably a reasonable assumption, but the uncertainty around the UNAIDS estimates should be acknowledged: if current coverage is overestimated, the necessary increase in the annual number of patients is also higher, and vice versa. In some countries, the UNAIDS upper limit of number of PLHIV in 2016 was up to 50% higher, and the lower limit 35% lower, than the point estimate. If other sources of uncertainty over the next years are taken into account, the margin in 2020 could be even wider. As an example, in a country where a three-fold increase in patients starting ART was needed to achieve the target using the point estimate for number of PLHIV, a 50% larger infected population in 2020 would lead to a five-fold increase needed instead, whereas with a 35% smaller infected population a 1.5-fold increase would be sufficient. Therefore, our results should be seen as an estimate of the magnitude, rather than accurate projections of the need of resources.
As the model does not take into account transmission, it also cannot consider the potential influence of achieving the 90-90-90 targets on incidence, mortality, and prevalence. Assessing the epidemiological impact of the 90-90-90 target was not within the scope of this study, but a sudden increase in ART and suppression coverage in the next years could also influence the size of the HIV infected population. It is however unlikely that the number of PLHIV would considerably change within the short period from 2016 to 2020, and the expected increase through prolonged life expectancy would be offset by the reduction in new infections.
Our model used the same parameter values for all countries with the exception of the ART initiation rate. We cannot therefore catch all differences between countries. Virological treatment failure was modelled using fixed parameters, based on analyses of mainly South African data. The model is therefore likely to be well applicable to many settings in southern Africa, but not to settings facing serious problems in keeping viral suppression. We estimated viral suppression only based on events that have long-term influence on viral load. We did not model viral load trajectories explicitly, nor did we take into account some potential causes of viraemia such as temporary poor adherence.
Conclusions
Our study has shown that the ambitious 90-90-90 target, ultimately meaning that 73% of all PLHIV would be virally suppressed by 2020, is realistically reachable in sub-Saharan Africa overall, but not in all countries. High-prevalence countries in East and Southern Africa have already reached a high level of ART coverage. The key challenges in these countries will therefore be to maximise viral suppression and retention by improving laboratory monitoring and counselling during treatment, implementing differentiated service delivery models, and establishing access to improved treatment options. Countries with lower HIV prevalence will need to improve the pace of scale-up of ART that in practice will require improved access and uptake of HIV testing. The gaps in the cascade from HIV infection through testing, diagnosis, linkage to care, ART initiation, and adequate retention and adherence, to sustained and virally suppressed ART, differ between the countries. It is critical that each country review in detail the status of their HIV epidemic and response and use this information to prioritise the interventions targeting the different steps on the cascade.
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